You are here

BridgeBio

Biopharma stocks go back to bleak

Biopharma stocks go back to bleak

EP Vantage

Apellis Pharmaceuticals

Protagonist Therapeutics

Reata Pharmaceuticals

Flag link:

BioMarin Answers BridgeBio's Challenge with sNDA for Achondroplasia

BioMarin Answers BridgeBio's Challenge with sNDA for Achondroplasia

BioSpace

Flag link:

BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study

BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study

Investors Business Daily

Flag link:

FDA Review: Phanes, Pfizer, GSK and More

FDA Review: Phanes, Pfizer, GSK and More

BioSpace

Eagle Pharmaceuticals

Galactin Therapeutics

Gilead Sciences

scPharmaceuticals

Flag link:

$2.4B BridgeBio/Helsinn Liver Cancer Deal Falls Apart

$2.4B BridgeBio/Helsinn Liver Cancer Deal Falls Apart

BioSpace

Flag link:

BridgeBio's CEO on staying alive, 'motherhood and apple pie'

BridgeBio's CEO on staying alive, 'motherhood and apple pie'

Fierce Biotech

Flag link:

When will biotech markets get better? BridgeBio fears they may stay 'pretty bad' until 2024

When will biotech markets get better? BridgeBio fears they may stay 'pretty bad' until 2024

Fierce Biotech

Flag link:

BridgeBio adds another $110M to coffers with voucher sale a day after mega BMS deal

BridgeBio adds another $110M to coffers with voucher sale a day after mega BMS deal

Fierce Biotech

priority review vouchers

Flag link:

A week after disclosing layoffs, BridgeBio nets a $90M upfront cancer R&D pact with Bristol Myers

A week after disclosing layoffs, BridgeBio nets a $90M upfront cancer R&D pact with Bristol Myers

Endpoints

Bristol Myers Squibb

Flag link:

‘Tis the Season: Job Cuts and C-Suite Shifts at Novartis, BridgeBio and Nektar

‘Tis the Season: Job Cuts and C-Suite Shifts at Novartis, BridgeBio and Nektar

BioSpace

Flag link:

BridgeBio says trial for acoramidis in transthyretin amyloidosis did not meet main goal

BridgeBio says trial for acoramidis in transthyretin amyloidosis did not meet main goal

Seeking Alpha

clinical trials

transthyretin amyloidosis

Flag link:

Bridgebio sets its heart on besting Pfizer

Bridgebio sets its heart on besting Pfizer

EP Vantage

transthyretin amyloid cardiomyopathy

Flag link:

BridgeBio Gets $750M on Credit to Fuel Long List of Programs

BridgeBio Gets $750M on Credit to Fuel Long List of Programs

Pharma Live

research and development

Flag link:

Bristol Myers Squibb catches the SHP2 wave in a new collaboration deal with BridgeBio

Bristol Myers Squibb catches the SHP2 wave in a new collaboration deal with BridgeBio

Endpoints

Bristol Myers Squibb

SHP2 inhibitors

Flag link:

With early phase 2 data, BridgeBio plots next steps for hypoparathyroidism drug

With early phase 2 data, BridgeBio plots next steps for hypoparathyroidism drug

Fierce Biotech

hypoparathyroidism

clinical trials

Flag link:

BridgeBio spins gold out of an Alexion castoff, scoring an FDA approval in rare metabolism disorder

BridgeBio spins gold out of an Alexion castoff, scoring an FDA approval in rare metabolism disorder

Endpoints

molybdenum cofactor deficiency type A

Flag link:

BridgeBio grabs a second priority review for the portfolio — giving Perceptive startup cause to celebrate

BridgeBio grabs a second priority review for the portfolio — giving Perceptive startup cause to celebrate

Endpoints

priority review

QED Therapeutics

Flag link:

Eyeing their first approval, BridgeBio sends their first drug to the FDA and lands a speedy review

Eyeing their first approval, BridgeBio sends their first drug to the FDA and lands a speedy review

Endpoints

priority review

Flag link:

Allergan ex-CEO Saunders takes board seat at BridgeBio

Allergan ex-CEO Saunders takes board seat at BridgeBio

Fierce Biotech

Flag link:

A Look at 5 Big and Interesting Biotech IPOs for 2019

A Look at 5 Big and Interesting Biotech IPOs for 2019

BioSpace

Adaptive Biotechnologies

Flag link:

Pages